SSKN - STRATA Skin Sciences, Inc.
| Previous Close | 1.8100 |
| Open | 1.8000 |
| Bid | 1.2000 x 1400 |
| Ask | 2.8200 x 900 |
| Day's Range | 1.6500 - 1.8000 |
| 52 Week Range | 1.6500 - 3.4300 |
| Volume | 212,015 |
| Avg. Volume | 72,178 |
| Market Cap | 54.619M |
| Beta (3Y Monthly) | 2.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2410 |
| Earnings Date | Apr 4, 2019 - Apr 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- GlobeNewswire
Strata Skin Sciences Receives Nasdaq Notice of Non-compliance
STRATA Skin Sciences, Inc. (SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced today that it had received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) on October 1, 2019 notifying the Company that it would be subject to delisting unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company timely requested a hearing earlier today. In the event the Company becomes current in the filing of its periodic reports prior to the hearing, the hearing can be canceled.
- GlobeNewswire
STRATA Skin Sciences to Participate in Ladenburg Thalmann 2019 Healthcare Conference
STRATA Skin Sciences (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference at the Sofitel Hotel in New York, on Tuesday, September 24th at 11:30 am Eastern Time. STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
- GlobeNewswire
STRATA Skin Sciences to Participate in H.C. Wainwright’s Annual Healthcare Conference
STRATA Skin Sciences (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the H. C. Wainwright Annual Healthcare Conference at the Lotte New York Palace Hotel, on Monday, September 9th at 3:25 pm Eastern Time. STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
- GlobeNewswire
STRATA Skin Sciences Receives Notice of Filing Delinquency from NASDAQ
As previously reported by the Company in its Notification of Late Filing on Form 12b-25, filed with the Commission on August 15, 2019, the Company was unable to file due to the issues related to liabilities related to state sales and use taxes related to the Company’s XTRAC laser business, and accounting of non-cash derivative liabilities arising from debentures issued by the Company in June 2015, which converted into shares of the Company’s Series C Preferred Stock in September 2017, as well as, stock purchase warrants issued in June of 2015 and July of 2014. This notice from Nasdaq has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market.
- GlobeNewswire
STRATA Skin Sciences Announces Preliminary Second Quarter 2019 Financial Results and Updates
STRATA Skin Sciences (SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced preliminary unaudited revenue results for the second quarter ended June 30, 2019. Financial results reported in this press release are preliminary. Final financial results and other disclosures will be reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, and may differ materially from the results and disclosures in this press release due to, among other things, the completion of final audit procedures related to the year ended December 31, 2018, including, but not limited to, those related to contingent or potential liabilities related to sales and use tax as well as potential non-cash derivative accounting treatment arising from debentures issued in June 2015 and converted to Series C Preferred Stock in September 2017, the occurrence of subsequent events, or the discovery of additional information.
- GlobeNewswire
STRATA Skin Sciences to Participate in Canaccord Genuity 39th Annual Growth Conference
STRATA Skin Sciences (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the Canaccord Genuity 39th Annual Growth Conference at the InterContinental Boston Hotel at 510 Atlantic Avenue, Boston, MA on Thursday, August 8th at 10:00 am Eastern Time. STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
- GlobeNewswire
STRATA Skin Sciences Announces Direct Distribution Contract with Kosmo Meditech in Korea
STRATA Skin Sciences, Inc. (“STRATA”) (SSKN), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the signing of a direct distribution contract with Kosmo Meditech for a combination of direct capital sales and direct recurring revenue sales in Korea.
- GlobeNewswire
STRATA Skin Sciences to Present at Upcoming Investor Conferences
Dr. Rafaeli’s participation will not be webcast, but the Company’s latest investor presentation is available in the investor’s section of the Company’s website at www.strataskinsciences.com. STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
- GlobeNewswire
STRATA Skin Sciences Announces Preliminary First Quarter 2019 Financial Results and Updates
STRATA Skin Sciences (SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced preliminary unaudited revenue results for the first quarter ended March 31, 2019. Financial results reported in this press release are preliminary. Final financial results and other disclosures will be reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and may differ materially from the results and disclosures in this press release due to, among other things, the completion of final audit procedures related to the year ended December 31, 2018, including, but not limited to, those related to contingent or potential liabilities related to sales and use tax as well as potential non-cash derivative accounting treatment arising from debentures issued in June 2015 and converted to Series C Preferred Stock in September 2017, the occurrence of subsequent events, or the discovery of additional information.
- GlobeNewswire
Strata Skin Sciences Receives Notice of Filing Delinquency from NASDAQ
STRATA Skin Sciences, Inc. (SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, received written notification from The NASDAQ Stock Market (“Nasdaq”) on April 3, 2019 that the Company is no longer in compliance with the Nasdaq Listing Rules since STRATA has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2018 (the “Annual Report”).
- GlobeNewswire
STRATA Skin Sciences Announces Preliminary Fourth Quarter and Full-Year 2018 Revenue Results
STRATA Skin Sciences, Inc. (SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today provided a corporate update and announced preliminary unaudited revenue and gross margin results for the fourth quarter and full year ended December 31, 2018. Financial results reported in this press release are preliminary. Final financial results and other disclosures will be reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and may differ materially from the results and disclosures in this press release due to, among other things, the completion of final audit procedures, including, but not limited to, those related to contingent or potential liabilities related to sales and use tax as well as potential non-cash derivative accounting treatment arising from debentures issued in June 2015 and converted to Series C Preferred Stock in September 2017, the occurrence of subsequent events, or the discovery of additional information.
- Zacks
Will Strata Skin (SSKN) Report Negative Q4 Earnings? What You Should Know
Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
STRATA Skin Sciences to Participate in Oppenheimer’s 29th Annual Healthcare Conference
HORSHAM, Pa., March 05, 2019 -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing,.
- GlobeNewswire
STRATA Skin Sciences to Participate in the BTIG MedTech, Life Science and Diagnostic Tools Conference
STRATA Skin Sciences (SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will participate in the BTIG MedTech, Life Science and Diagnostic Tools Conference, February 27th and February 28th in Snowbird, Utah. STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
- Simply Wall St.
Is There Now An Opportunity In STRATA Skin Sciences, Inc. (NASDAQ:SSKN)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! STRATA Skin Sciences, Inc. (NASDAQ:SSKN), which isRead More...
- Simply Wall St.
How Financially Strong Is STRATA Skin Sciences, Inc. (NASDAQ:SSKN)?
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) is a small-cap stock with a market capitalization of US$94m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, Read More...
- Thomson Reuters StreetEvents
Edited Transcript of SSKN earnings conference call or presentation 13-Nov-18 1:30pm GMT
Q3 2018 STRATA Skin Sciences Inc Earnings Call
- Simply Wall St.
A Look At The Fair Value Of STRATA Skin Sciences, Inc. (NASDAQ:SSKN)
Does the December share price for STRATA Skin Sciences, Inc. (NASDAQ:SSKN) reflect it's really worth? Today, I will calculate the stock's intrinsic value by taking the foreast future cash flows Read More...
- GlobeNewswire
STRATA Skin Sciences Secures Exclusive License for Treating Vitiligo Using an Excimer Laser
STRATA Skin Sciences (SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has reached agreement with an internationally acclaimed health institution regarding U.S. Patent 6,979,327 (the “327” patent) and U.S. Patent 7,261,729 B2 for the “Treatment of Vitiligo.” The agreement clarifies STRATA's exclusive license to develop, make, use, sell, offer for sale, import as well as defend the patents. The patents pertain to a novel treatment for vitiligo, using an excimer laser that emits light in the UVB range.
- GlobeNewswire
Factors of Influence in 2018, Key Indicators and Opportunity within Naked Brand Group, Quest Resource Holding, Rand Capital, RCM Technologies, Strata Skin Sciences, and Nova Lifestyle — New Research Emphasizes Economic Growth
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire
STRATA Skin Sciences Reports Third Quarter 2018 Financial Results
Revenue growth momentum continues with further improvement in gross margins and positive operating cash flow for the quarter Conference call and webcast, today at 8:30 am.
- PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating STRATA Skin Sciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , Nov. 7, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
- Simply Wall St.
Does The STRATA Skin Sciences Inc (NASDAQ:SSKN) Share Price Fall With The Market?
If you own shares in STRATA Skin Sciences Inc (NASDAQ:SSKN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a Read More...
- Zacks
Will Strata Skin (SSKN) Report Negative Earnings Next Week? What You Should Know
Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
